SEC SCHEDULE 13G

Company

Aligos Therapeutics, Inc.

Filed

October 22, 2020

Accession Number

0001787092-20-000006

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →